Videos

At the 65th ASH Annual Meeting, David Andorsky, MD, discussed an interim analysis of the AIM4CML trial, which indicated that asciminib treatment continued to demonstrate efficacy and tolerability among patients with CML chronic phase.

At the 65th ASH Annual Meeting, Yucai Wang, MD, PhD, discusses trial findings that first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy yielded efficacious outcomes among patients with mantle cell...

Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.

Fresia Pareja, MD, PhD, discussed novel mechanisms of CDH1 inactivation discovered using an artificial intelligence based system.

David Rimm, MD, PhD, discussed study results which identified quantitative multiplex immunofluorescence assay as an optimal way to detect TROP2 and HER2 expression in breast cancer.

At the 65th American Society of Hematology Annual Meeting in San Diego, California, Robert M Rifkin, MD, discusses a study analyzing the outpatient administration of step-up doses of BCMA-targeting bispecific antibody teclistamab.

Hannah Cox, PhD, HCLD, discussed clinical findings from genetic analyses of Puerto Rican patients with a personal/family history of breast cancer.

Hatem Azim, MD, PhD, discussed results from the POSITIVE trial.

Seth Wander, MD, PhD, discussed results from the phase 1b cohort of a phase 1/2 clinical trial, demonstrating that vepdegestrant plus palbociclib is clinically effective among patients with heavily pretreated, ER-positive, HER2-negative...

Lajos Pusztai, MD, DPhil, discussed results from the DARE study which analyzed the clinical utility of ctDNA monitoring during adjuvant endocrine therapy to detect molecular relapse before apparent recurrence.